Baird starts Immunocore at outperform, calls it “rare find” in biotech space (IMCR)
DNY59 Baird initiated coverage of Immunocore (NASDAQ:IMCR) with an outperform rating, calling a “rare find” in the smid-cap biotech space due to its growing top-line, “meaningful” near-term catalysts and "substantial" cash runway. Baird…
